血清神经丝轻链联合心肌肌钙蛋白T提升肌萎缩侧索硬化诊断准确性
该研究回顾性分析293例ALS患者、85例神经退行性疾病对照和29例健康对照,并采用501例ALS验证队列。结果显示sNfL联合cTnT鉴别ALS与神经退行性疾病对照的AUC达0.90,优于cTnT单用(0.77),且生物标志物阴性患者病程更长、进展更慢。
要点
- sNfL联合cTnT可提高ALS与神经退行性疾病对照的鉴别准确性。
- cTnT单独鉴别ALS与疾病对照的AUC为0.77,联合后升至0.90。
- 生物标志物阴性ALS患者病程更长、进展速率更低。
核心结论
- sNfL单用区分ALS与健康对照表现优秀,但区分ALS与神经退行性疾病对照仅中等,联合cTnT可提升诊断准确性并识别预后不同亚组。
研究设计与样本
- 回顾性分析293例ALS患者、85例神经退行性疾病对照和29例健康对照,并用501例ALS验证队列确认可重复性。
主要发现
- sNfL区分ALS与健康对照的AUC为0.94,区分神经退行性疾病对照的AUC为0.82。
- sNfL联合cTnT区分ALS与神经退行性疾病对照的AUC为0.90,cTnT单用AUC为0.77。
- 验证队列显示相似AUC。
- 生物标志物阴性ALS患者病程为73.0个月,长于阳性患者的18.0个月(p=0.0003)。
- 生物标志物阴性ALS患者进展速率为0.19分/月,低于阳性患者的0.70分/月(p<0.0001)。
关键数值与推荐
- 采用约登指数确定ALS特异性cTnT切点为8.35ng/L,并用于亚组分析。
临床怎么用
- 在鉴别ALS与神经退行性疾病对照时,可考虑联合检测sNfL与cTnT以提高诊断准确性。
- cTnT切点8.35ng/L可用于识别预后不同的ALS亚组,生物标志物阴性者病程更长、进展更慢。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We aimed to evaluate the clinical utility of serum neurofilament light chain (sNfL) and cardiac troponin T (cTnT) in amyotrophic lateral sclerosis (ALS) and assess whether their combination improves diagnostic accuracy. METHODS: We retrospectively analyzed 293 ALS patients, 85 neurodegenerative disease controls, and 29 healthy controls. A validation cohort of 501 ALS patients was analyzed to confirm reproducibility of the results. Receiver operating characteristic (ROC) curve analysis was performed for sNfL, cTnT, and their combination, and the area under the curve (AUC) was compared across groups. An ALS-specific cTnT cut-off of 8.35ng/L was determined using the Youden index and applied in subgroup analyses, in which "biomarker-negative" ALS patients were compared to "biomarker-positive" patients regarding disease duration and progression. RESULTS: sNfL showed excellent performance in discriminating ALS patients from healthy controls (AUC = 0.94), but only moderate performance in discriminating neurodegenerative disease controls (AUC = 0.82). Combining sNfL and cTnT improved diagnostic accuracy for ALS over neurodegenerative controls, with an AUC of 0.90, whereas cTnT alone showed an AUC of 0.77. The validation cohort showed similar AUCs. "Biomarker-negative" ALS patients had a longer disease duration (73.0 vs 18.0 months, p = 0.0003) and a lower progression rate (0.19 vs 0.70 points per months, p < 0.0001) than "biomarker-positive" patients. INTERPRETATION: Although sNfL alone performs well in distinguishing ALS from healthy controls, repurposing cTnT for ALS provides additional value in discriminating ALS from disease controls. The combination of sNfL and cTnT improves diagnostic accuracy and may help identify prognostically distinct ALS subgroups. ANN NEUROL 2026;99:408-417.
引用
- Lindenborn P, Fabian R, Grehl T, et al. Combination of Serum Neurofilament Light Chain and Serum Cardiac Troponin T as Biomarkers Improves Diagnostic Accuracy in Amyotrophic Lateral Sclerosis. Ann Neurol. 2025. PMID: 41133969. doi:10.1002/ana.78066
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。